Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Tamara Ecclestone is criticised as her daughter Fifi, 10, heads out wearing heavy make
Double European weightlifting champion Pielieshenko killed in Ukraine war
Nutrition experts add traffic light health labels to famous food paintings
Tamara Ecclestone is criticised as her daughter Fifi, 10, heads out wearing heavy make
Macron sets Ukraine war as top priority as China's Xi Jinping arrives in France
Nutrition experts add traffic light health labels to famous food paintings
Minnesota legislators consider constitutional amendment to protect abortion and LGBTQ rights
Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia
Tom Brady roast: Netflix live event features Robert Kraft and Bill Belichick reunion
National Television Awards 2024 nominations: Michelle Keegan and Leo Woodall go head
WNBA expansion franchise Golden State hires Ohemaa Nyanin as its general manager